2.
Comparison of clinicopathological features among both of IFCC groups
| Clinicopathological features | Positive | Negative | P |
| IFCC, intraperitoneal free cancer cell; BMI, body mass index; HER2, human epidermal growth factor receptor; PDL, programmed cell death ligand; MMR, mismatch repair. | |||
Age (
 ) (year)
|
58±12 | 57±11 | 0.664 |
BMI (
 ) (kg/m2)
|
22.49±3.53 | 22.41±3.56 | 0.954 |
| Gender | 0.770 | ||
| Male | 49/71 | 23/32 | |
| Female | 22/71 | 9/32 | |
| Differentiation | 0.606 | ||
| High | 2/70 | 0/30 | |
| Middle | 15/70 | 5/30 | |
| Low | 43/70 | 20/30 | |
| Undifferentiation | 10/70 | 5/30 | |
| Lauren type | 0.004 | ||
| Intestinal | 31/66 | 6/30 | |
| Diffused | 24/66 | 10/30 | |
| Mixed | 11/66 | 14/30 | |
| Vascular invasion | 0.179 | ||
| Positive | 35/60 | 13/30 | |
| Negative | 25/60 | 17/30 | |
| Perineural invasion | 0.648 | ||
| Positive | 37/60 | 17/30 | |
| Negative | 23/60 | 13/30 | |
| Tumor stage | 0.454 | ||
| T1a | 4/60 | 2/0 | |
| T1b | 7/60 | 5/30 | |
| T2 | 10/60 | 2/30 | |
| T3 | 21/60 | 8/30 | |
| T4a | 16/60 | 12/30 | |
| T4b | 2/60 | 1/30 | |
| Node lymph metastasis | 0.728 | ||
| N0 | 22/60 | 13/31 | |
| N1 | 10/60 | 6/31 | |
| N2 | 14/60 | 4/31 | |
| N3a | 10/60 | 5/31 | |
| N3b | 4/60 | 3/31 | |
| Conventional cytology | 0.415 | ||
| Positive | 10/71 | 2/32 | |
| Negative | 61/71 | 30/32 | |
| Pathology | 0.063 | ||
| Positive | 18/71 | 3/32 | |
| Negative | 53/71 | 29/32 | |
| Neoadjuvant group | 0.562 | ||
| Positive | 14/68 | 8/31 | |
| Negative | 54/68 | 23/31 | |
| HER2 expression | 0.295 | ||
| 0 | 33/58 | 12/29 | |
| 1+ | 10/58 | 10/29 | |
| 2+ | 9/58 | 2/29 | |
| 3+ | 6/58 | 5/29 | |
| Ki67 index (%) | 0.502 | ||
| 0−25 | 4/58 | 1/29 | |
| 26−50 | 7/58 | 4/29 | |
| 51−75 | 26/58 | 17/29 | |
| 76−100 | 21/58 | 7/29 | |
| PDL1 expression | 0.543 | ||
| Positive | 8/50 | 6/24 | |
| Negative | 42/50 | 18/24 | |
| MMR | 1.000 | ||
| Positive | 57/58 | 29/29 | |
| Negative | 1/58 | 0/29 | |